(lp0
S'InterMune Inc. Shareholders Can Now Breathe Easier Thanks to Roche Motley Fool - Aug 25, 2014 Over the weekend, we witnessed the latest sizable deal in the biotech sector go down with global pharmaceutical giant Roche  announcing it would pay $8.3 billion in cash, or $74 per share, to acquire InterMune ,&nbsp;...Roche Holding Agrees to Buy InterMune for $8.3 Billion - BloombergRoche In $8.3 Billion Deal To Acquire InterMune Inc  - ValueWalk'
p1
aS'InterMune to Divest Actimmune  PR Newswire  - May 21, 2012 BRISBANE, Calif., May 21, 2012 /PRNewswire/ -- InterMune, Inc.  today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited  to sell its rights to Actimmune  in a&nbsp;...'
p2
aS'InterMune Reports Second Quarter 2014 Financial Results and Business Highlights PR Newswire  - Aug 6, 2014 InterMune reported Esbriet  revenue in the second quarter of 2014 of $35.7 million, compared with $14.4 million in the second quarter of 2013, an increase of 148 percent.'
p3
aS'Ex-InterMune executive, friend found liable for insider trading Daily Mail - Nov 14, 2016 Nov 14  - A former executive at pharmaceutical company InterMune Inc and a British restaurant owner were found liable on Monday on U.S.'
p4
aS"InterMune Is Set To Outperform Its Main Competitor Seeking Alpha - Feb 12, 2014 InterMune's  sole product pirfenidone  is an orally active, small molecule drug currently seeking approval from the FDA for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease."
p5
aS"AbbVie, InterMune Sue to Block Clinical-Trial Data Release Bloomberg - Mar 11, 2013 AbbVie Inc., the drugmaker that was split off from Abbott Laboratories at the start of this year, and biotechnology company InterMune Inc. sued the European Union's pharmaceuticals regulator in a bid to block publication of clinical-trial data. AbbVie ..."
p6
aS'InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic ... PR Newswire  - Feb 25, 2014 BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc.  today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis , demonstrated that pirfenidone&nbsp;...InterMune Inc.  Shares More than Double then Slump by 15% - WallStreetPRInterMune Lung Drug Is Successful in New Trial - New York Times'
p7
aS"After big sale to Roche, InterMune boss jumps to venture capital San Francisco Business Times  - Jan 8, 2015 The move comes as Roche, the Swiss parent company of South San Francisco's Genentech Inc., starts consolidating InterMune's operations. It told 170 of the Brisbane company's 450 workers in the week before Christmas that their jobs would be eliminated&nbsp;...Sofinnova Ventures Adds Daniel G. Welch to Life Science Investing Team - PR Newswire "
p8
aS'Pharma Co. Shionogi Sues InterMune Over Drug Royalties Law360  - Jul 10, 2012 Law360, New York  -- Japanese pharmaceutical company Shionogi &amp; Co. Ltd. sued InterMune Inc. in California federal court on Thursday for allegedly bilking it out of royalties from sales of a lung disease treatment on which ...'
p9
aS"4 winners, 3 losers in Roche's $8.3 billion takeover of InterMune San Francisco Business Times  - Sep 2, 2014 Company B, the company in an InterMune SEC filing whose CEO was scheduled to talk to InterMune's Welch but cancelled."
p10
a.